ISSN 1941-5923

American Journal of Case Reports

Current Volume 15, 2014

Published: 2014-04-14

Background: Studies of the efficacy of the combination of the incretin mimetic liraglutide and the SGLT2 inhibitor canagliflozin or indeed studies of the combination of any incretin mimetic with an SGLT2 inhibitor have neither been performed nor published. Pharmacologically, the combination of an incretin-mimetic and an SGLT2-receptor blocker should result in a more significant weight loss and a greater reduction in postprandial glucose and HbA1c.
Case Report: An insulin-dependent type 2 diabetic patient with multiple diabetic complications was placed on the combination of liraglutide and canagliflozin and 4 weeks later was able to discontinue insulin. In addition, in spite of discontinuing insulin, his HbA1c dropped from 7.0% to 6.8%, and he had reductions in body (weight from 247 to 218...

Keywords: Diabetes Mellitus, Type 2, Incretins, Sodium-Glucose Transporter 2


Related Articles

Coming Soon...

Published: 2014-04-10

Clinical and angiographic findings in Moya Moya

Aman Sharma, Neil Soneji, George Farah

Am J Case Rep 2014;15:147-151

DOI: 10.12659/AJCR.890222

Published: 2014-04-07

Chorea, Hyperglycemia, Basal Ganglia Syndrome (C-H-BG) in an uncontrolled diabetic patient with normal gl...

Jorge Bizet, Chad J. Cooper, Rapheal Quansah, Emmanuel Rodriguez, Mohamed Teleb, German T. Hernandez

Am J Case Rep 2014;15:143-146

DOI: 10.12659/AJCR.890179